Sumitomo Pharma Co., Ltd. DPM.F Stock
Sumitomo Pharma Co., Ltd. Price Chart
Sumitomo Pharma Co., Ltd. DPM.F Financial and Trading Overview
Sumitomo Pharma Co., Ltd. stock price | 1.64 EUR |
Previous Close | 4.24 EUR |
Open | 4.12 EUR |
Bid | 4.1 EUR x 60000 |
Ask | 4.3 EUR x 60000 |
Day's Range | 4.12 - 4.12 EUR |
52 Week Range | 4.12 - 8.1 EUR |
Volume | 90 EUR |
Avg. Volume | 20 EUR |
Market Cap | 1.67B EUR |
Beta (5Y Monthly) | 0.436781 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.65 EUR |
Forward Dividend & Yield | 0.1 (2.25%) |
Ex-Dividend Date | March 30, 2023 |
1y Target Est | N/A |
DPM.F Valuation Measures
Enterprise Value | 192.96B EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.0029994117 |
Price/Book (mrq) | 0.0040242076 |
Enterprise Value/Revenue | 0.347 |
Enterprise Value/EBITDA | 62.63 |
Trading Information
Sumitomo Pharma Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.436781 |
52-Week Change | -39.57% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.1 EUR |
52 Week Low | 4.12 EUR |
50-Day Moving Average | 5.12 EUR |
200-Day Moving Average | 6.27 EUR |
DPM.F Share Statistics
Avg. Volume (3 month) | 20 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 397.29M |
Float | 176.54M |
Short Ratio | N/A |
% Held by Insiders | 58.59% |
% Held by Institutions | 19.94% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 21 |
Trailing Annual Dividend Yield | 495.28% |
5 Year Average Dividend Yield | 186.00% |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | -13.41% |
Operating Margin (ttm) | -6.87% |
Gross Margin | 68.58% |
EBITDA Margin | 0.55% |
Management Effectiveness
Return on Assets (ttm) | -1.95% |
Return on Equity (ttm) | -17.90% |
Income Statement
Revenue (ttm) | 555.54B EUR |
Revenue Per Share (ttm) | 1398.33 EUR |
Quarterly Revenue Growth (yoy) | -25.50% |
Gross Profit (ttm) | N/A |
EBITDA | 3.08B EUR |
Net Income Avi to Common (ttm) | -74511998976 EUR |
Diluted EPS (ttm) | -0.14 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 143.48B EUR |
Total Cash Per Share (mrq) | 361.14 EUR |
Total Debt (mrq) | 334.72B EUR |
Total Debt/Equity (mrq) | 82.28 EUR |
Current Ratio (mrq) | 1.025 |
Book Value Per Share (mrq) | 1023.804 |
Cash Flow Statement
Operating Cash Flow (ttm) | 11.94B EUR |
Levered Free Cash Flow (ttm) | 101.77B EUR |
Profile of Sumitomo Pharma Co., Ltd.
Country | Germany |
State | N/A |
City | Osaka |
Address | 6-8, Doshomachi 2-chome |
ZIP | 541-0045 |
Phone | 81 6 6203 5321 |
Website | https://www.sumitomo-pharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Q&A For Sumitomo Pharma Co., Ltd. Stock
What is a current DPM.F stock price?
Sumitomo Pharma Co., Ltd. DPM.F stock price today per share is 1.64 EUR.
How to purchase Sumitomo Pharma Co., Ltd. stock?
You can buy DPM.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sumitomo Pharma Co., Ltd.?
The stock symbol or ticker of Sumitomo Pharma Co., Ltd. is DPM.F.
Which industry does the Sumitomo Pharma Co., Ltd. company belong to?
The Sumitomo Pharma Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Sumitomo Pharma Co., Ltd. have in circulation?
The max supply of Sumitomo Pharma Co., Ltd. shares is 404.62M.
What is Sumitomo Pharma Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Sumitomo Pharma Co., Ltd. PE Ratio is now.
What was Sumitomo Pharma Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Sumitomo Pharma Co., Ltd. EPS is -4.65 EUR over the trailing 12 months.
Which sector does the Sumitomo Pharma Co., Ltd. company belong to?
The Sumitomo Pharma Co., Ltd. sector is Healthcare.